000931 Beijing Centergate Technologies
- 4.52
- +0.08+1.80%
Beijing Centergate Technologies News
Zhongguancun (000931.SZ): Subsidiary company Duoduo Pharmaceutical Ambroxol Hydrochloride Injection received the “Notice of Acceptance” from the State Drug Administration
Gelonghui, April 29丨Zhongguancun (000931.SZ) announced that Duoduo Pharmaceutical Co., Ltd. (hereinafter: Duoduo Pharmaceutical), a subsidiary of the company, recently received the “Notice of Acceptance” of the registration application for the chemical generic drug ambroxol hydrochloride injection issued by the China Drug Administration (hereinafter referred to as the State Drug Administration).
Zhongguancun (000931.SZ): Net profit of 116.311 million yuan in the first quarter increased 22.88% year-on-year
Gelonghui, April 26 | Zhongguancun (000931.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 606 million yuan, up 3.06% year on year; net profit attributable to shareholders of listed companies was 116.311 million yuan, up 22.88% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.6067 million yuan, down 1.66% year on year; basic earnings per share were 0.0154 yuan.
Zhongguancun (000931.SZ): Subsidiary company Beijing Huasubanbazol API approved for listing
Gelonghui, April 22丨Zhongguancun (000931.SZ) announced that Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter: Beijing Huasu), a subsidiary of Beijing Zhongguancun Science and Technology Development (Holdings) Co., Ltd. (hereinafter referred to as the Company), recently passed the technical review by the Drug Evaluation Center of the State Drug Administration (CDE) and obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration). Bifonazole raw materials are indicated for antifungal infections. Bifonazol (Bifonaz
Zhongguancun (000931.SZ): Shandong huasuglipizide dispersible tablets are considered to have passed the consistency evaluation
Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Recently, Shandong Huasu Pharmaceutical Co., Ltd. (hereinafter referred to as Shandong Huasu), a subsidiary of the company, received the “Drug Supplement Application Approval Notice” (Notice Number: 2024B01608) approved and issued by the State Drug Administration and learned that “glipyrazine dispersible tablets” (registered trademark: Yuantan) (specification: 5mg) produced by Shandong Huasu are treated as having passed the consistent evaluation of the quality and efficacy of generic drugs. Glipizide dispersible tablets (specification: 5mg) are second-generation sulfonylureas oral hypoglycemic agents. Oral absorption is rapid and complete, and half-life
Zhongguancun (000931.SZ): Subsidiary companies received the “Notice of Acceptance” from the State Drug Administration for the consistency evaluation of Beijing Huasu naloxone hydrochloride injection and the Shandong Huasu metoprolol succinate API applicat
Gelonghui, April 3, 丨 Zhongguancun (000931.SZ) announced that recently, Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter: Beijing Huasu), the holding subsidiary of Beijing Zhongguancun Sihuan Pharmaceutical Development Co., Ltd., a wholly-owned subsidiary of the company, and Shandong Huasu Pharmaceutical Co., Ltd. (hereinafter: Shandong Huasu) received the “Notice of Acceptance” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration), naloxone hydrochloride injection (specifications: 1ml: 0.4 mg, 1ml: 1mg, 2ml) Application for sexual evaluation Acceptance and metformin succinate
Zhongguancun (000931.SZ): Signed a cooperation agreement with the Jiamusi High-tech Zone Management Committee for small-volume injection and oral liquid formulation projects
Gelonghui, Feb. 29丨Zhongguancun (000931.SZ) announced that the company and the Jiamusi High-tech Industrial Development Zone Management Committee (Jiamusi High-tech Zone Management Committee for short) signed the “Small Volume Injection and Oral Liquid Formulation Project Cooperation Agreement” in Jiamusi City on February 29, 2024. The company is committed to a development and business strategy centered on “Medicine and Health”. In order to enhance the production capacity of traditional Chinese medicine injections and oral liquids and further enhance its core competitiveness, the company expects to invest about 80 million yuan in Jiamusi City, Heilongjiang Province It belongs to the company Duoduo Pharmaceutical Co., Ltd. (abbreviation: Duoduo Pharmaceutical
Zhongguancun (000931.SZ): Subsidiary company Shandong Huasu signs office lease contract with Gome Real Estate
Gelonghui, Feb. 28: Zhongguancun (000931.SZ) announced that after review and approval at the 12th Interim Meeting of the 6th Board of Directors of the Company in 2017, the company signed an office lease contract with Gome Real Estate Holdings Co., Ltd. (abbreviation: Gome Real Estate) to rent an office space with a construction area of 1,168.31 square meters as an office space. The monthly rent for the leased property is RMB 227,820.45. The tax-inclusive property fee is RMB 105,147.90, and the rental period is two years. After review and approval at the first interim meeting of the 7th board of directors of the company in 2020,
A subsidiary company of Zhongguancun (000931.SZ) changed the production license of Beijing Huasu Pharmaceutical and passed the drug GMP compliance inspection
Zhongguancun (000931.SZ) issued an announcement. The company's subsidiary, Beijing Huasu Pharmaceutical Co., Ltd. (Beijing Hua...
Zhongguancun (000931.SZ): Some directors and executives increased their holdings by a total of 21,600 shares
Gelonghui, Feb. 4: Zhongguancun (000931.SZ) announced that recently, Beijing Zhongguancun Technology Development (Holdings) Co., Ltd. received notices from Director and President Mr. Hou Zhanjun, Vice President and Financial Director Mr. Song Xuewu, and Mr. Huang Zhiyu, Vice President and Board Secretary to enhance investor confidence based on confidence in the company's future steady development and recognition of long-term investment value, and used its own funds to buy the company's shares through the Shenzhen Stock Exchange stock trading system, increasing the total number of shares by 21,600 shares.
Zhongguancun (000931.SZ): Shandong Huasu once again obtained the high-tech enterprise certificate
Gelonghui, January 24 | Zhongguancun (000931.SZ) announced that Shandong Huasu Pharmaceutical Co., Ltd. (abbreviation: Shandong Huasu), the grandson of Beijing Zhongguancun Sihuan Pharmaceutical Development Co., Ltd., a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Shandong Provincial Department of Science and Technology, the Shandong Provincial Department of Finance, and the Shandong Taxation Bureau of the State Administration of Taxation. Certificate number: GR202337001016. The certificate is valid for three years.
Zhongguancun (000931.SZ): 2023 pre-profit of 45 million yuan to 50 million yuan, reversing year-on-year losses
Gelonghui, January 19 | Zhongguancun (000931.SZ) announced the 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was about 45 million yuan to 50 million yuan, a loss of 42,8524 million yuan for the same period last year, turning a year-on-year loss into a profit; net profit profit of about 32 million yuan to 37 million yuan after deducting non-recurring profit and loss, a loss of 50.02048 million yuan per share; basic profit income per share was about 0.0598 yuan/share to 0.0664 yuan/share. The company expects net profit attributable to shareholders of listed companies during the reporting period to be 4,500
Zhongguancun (000931.SZ): Oxycodone hydrochloride extended-release tablets under development (specifications 10mg, 40mg) are expected to be marketed in the fourth quarter of 2026
Gelonghui January 12丨Zhongguancun (000931.SZ) was surveyed by specific subjects on January 11, 2024, on “Expected marketing time for oxycodone hydrochloride sustained-release tablets and aminophenol oxycodone tablets under development?” The company replied that the company is actively promoting relevant research and development progress. The estimated marketing time for oxycodone hydrochloride extended-release tablets (specifications: 10 mg, 40 mg) under development is expected in the fourth quarter of 2026, and aminophen oxycodone tablets (specifications: acetaminophen 325 mg, oxycodone hydrochloride 5 mg) is expected to be marketed in the third quarter of 2026. The above estimated time is based on national drug administration regulations and the company's R&D progress
Zhongguancun (000931.SZ): Currently, the main OTC products are silidiodium tablets (product name: Huasu tablets), phenyclononyl hydrochloride tablets (product name: Fisele), and lactobacillins tablets
Gelonghui, January 12, 丨 Zhongguancun (000931.SZ) was surveyed by specific subjects on January 11, 2024. Regarding “the company's main OTC products,” the company replied that the company's OTC products mainly cover the treatment fields of oral cavity, motion sickness, skin, digestion, etc. Currently, the main OTC products are silidiodium tablets (trade name: Huasin tablets), and lactobacillins.
Zhongguancun (000931.SZ): Shandong Huasu, a subsidiary company, benidipine hydrochloride tablets (4mg, 2mg) passed the consistency evaluation
Gelonghui, December 25 | Zhongguancun (000931.SZ) announced that recently, Shandong Huasu Pharmaceutical Co., Ltd. (Shandong Huasu), a subsidiary of the company, received the “Drug Supplement Application Approval Notice” (Notice No.: 2023B06429, 2023B06430) approved and issued by the State Drug Administration and learned that “benidipine hydrochloride tablets” (specifications: 4mg, 2mg) produced by Huasu Shandong have passed the consistent evaluation of the quality and efficacy of generic drugs.
Some drugs in Zhongguancun (000931.SZ) entered the national medical insurance catalogue
Zhongguancun (000931.SZ) announced that recently, the National Health Insurance Administration and the Ministry of Human Resources and Social Security issued “On Printing...
Zhongguancun (000931.SZ): Duoduo Pharmaceutical's montmorillonite obtained a drug registration certificate
On December 20, Gelonghui (000931.SZ) announced that Duoduo Pharmaceutical Co., Ltd. (abbreviation: Duoduo Pharmaceutical), a subsidiary of the company, received the “Drug Registration Certificate” approved and issued by the State Drug Administration with a certificate number 2023S02007, and the “montmorillonite” (specification: 3 grams per bag) developed by Duoduo Pharmaceutical passed the generic drug registration application. Montmorillonite is used for acute and chronic diarrhea in adults and acute diarrhea in children. The main component of montmorillonite dispersion is montmorillonite, a layered aluminosilicate mineral. This product was first developed by IPSENPHARMA and was developed in 1975
Zhongguancun (000931.SZ): Jiujiu Taihe plans to buy Beijing Jinzun's fixed assets for 1.5 million yuan
Glonghui December 11丨Zhongguancun (000931.SZ) announced that in order to meet daily business needs, Beijing Taihe Pension Service Industry Development Co., Ltd. (abbreviation: Jiujiu Taihe), a wholly-owned subsidiary of Beijing Huasutang Pension Industry Investment Co., Ltd. (abbreviation: Jiujiu Taihe), plans to sign a “sales contract” with Beijing Jinzun Green Agriculture Technology Development Co., Ltd. (abbreviation: Beijing Jinzun). Jiujiu Taihe plans to purchase fixed assets of Beijing Jinzun for 1.5 million yuan, mainly furniture and electrical appliances. The source of capital is the company's own capital.
Zhongguancun (000931.SZ): Duoduo Pharmaceutical once again obtained the high-tech enterprise certificate
Gelonghui on December 4 | Zhongguancun (000931.SZ) announced that Duoduo Pharmaceutical Co., Ltd. (hereinafter: Duoduo Pharmaceutical), a holding subsidiary of Beijing Zhongguancun Sihuan Pharmaceutical Development Co., Ltd., a wholly-owned subsidiary of the company, recently received the “High-tech Enterprise Certificate” jointly issued by the Heilongjiang Provincial Department of Science and Technology, the Heilongjiang Provincial Department of Finance, and the State Administration of Taxation and the Heilongjiang Provincial Taxation Bureau. Certificate number: GR202323000516. The certification time is October 16, 2023, and is valid for three years.
Zhongguancun (000931.SZ): “Tramadol Hydrochloride” was selected as the 2023 Single Champion Product List for the Manufacturing Industry of Heilongjiang Province
Zhongguancun (000931.SZ) announced that the company recently received the “On...” issued by the Heilongjiang Provincial Department of Industry and Information Technology
“Thai Traditional Chinese Medicine Hospital” under Zhongguancun (000931.SZ) was changed to a designated medical institution with secondary medical insurance in Beijing
Zhongguancun (000931.SZ) issued a notice to strengthen the management of agreements with designated medical institutions for medical insurance in Beijing...
Analysis
Price Target
No Data
